Table 1.
Baseline characteristics in study patients with and without events
| Total (n = 1225) | Non-events (n = 1122) | Events (n = 103) | p value | ||
|---|---|---|---|---|---|
| Clinical characteristics | |||||
| Age (years) | 57.8 ± 10.1 | 57.7 ± 10.0 | 58.5 ± 10.8 | 0.419 | |
| Male sex | 833 (68.0) | 765 (68.3) | 68 (66.0) | 0.653 | |
| BMI (kg/m2) | 25.9 ± 3.3 | 25.9 ± 3.2 | 26.0 ± 4.1 | 0.704 | |
| Hypertension | 854 (69.7) | 781 (69.6) | 73 (70.9) | 0.789 | |
| Family history of CAD | 289 (23.6) | 275 (24.5) | 14 (13.6) | 0.013 | |
| Diabetes mellites | 377 (30.8) | 327 (29.1) | 50 (48.5) | < 0.001 | |
| Current smoker | 481 (39.3) | 440 (39.2) | 41 (39.8) | 0.907 | |
| Drinking | 284 (23.2) | 261 (23.3) | 23 (22.3) | 0.830 | |
| Laboratory parameters | |||||
| FPG (mmol/L) | 5.9 ± 1.9 | 5.9 ± 1.8 | 6.3 ± 3.1 | 0.042 | |
| HbA1C (%) | 6.2 ± 1.1 | 6.2 ± 1.1 | 6.4 ± 1.1 | 0.036 | |
| ALT (U/L) | 20(15,29) | 20 (15,29) | 20 (14,31) | 0.905 | |
| Creatinine (μmol/L) | 77.7 ± 17.5 | 77.6 ± 16.9 | 79.1 ± 23.0 | 0.408 | |
| TC (mmol/L) | 4.82 ± 0.96 | 4.80 ± 0.95 | 5.02 ± 0.95 | 0.028 | |
| TG (mmol/L) | 1.61 (1.16,2.32) | 1.6 (1.15,2.31) | 1.72 (1.31,2.43) | 0.215 | |
| HDL-C (mmol/L) | 1.09 ± 0.32 | 1.09 ± 0.32 | 1.15 ± 0.38 | 0.060 | |
| LDL-C (mmol/L) | 3.15 ± 0.85 | 3.13 ± 0.85 | 3.35 ± 0.85 | 0.013 | |
| PCSK9 (ng/mL) | 234.52 (194.79,276.13) | 232.99 (193.72,274.16) | 264.26 (219.45,309.86) | < 0.001 | |
| Fibrinogen (μg/mL) | 3.1 ± 0.8 | 3.1 ± 0.7 | 3.3 ± 1.1 | 0.006 | |
| NT-proBNP (pg/mL) | 51.9 (31.0,109.3) | 50.9 (30.1,111.0) | 58.1 (38.1,96.7) | 0.172 | |
| Diseased vessels | |||||
| One vessel | 438 (35.8) | 411 (36.6) | 27 (26.2) | ||
| Two vessels | 365 (29.8) | 340 (30.3) | 25 (24.3) | ||
| Three vessels | 422 (34.4) | 371 (33.1) | 51 (49.5) | ||
| LVEF (%) | 64.7 ± 6.7 | 64.7 ± 6.7 | 64.8 ± 6.6 | 0.882 | |
| Gensini score | 27 (11,44) | 26 (10,42) | 35.08 (18,60) | 0.003 | |
| Medications | |||||
| Aspirin | 464 (37.9) | 431 (38.4) | 33 (32.0) | 0.202 | |
| Clopidogrel | 130 (10.6) | 123 (11.0) | 7 (6.8) | 0.189 | |
| ACEI/ARB | 252 (20.6) | 235 (20.9) | 17 (16.5) | 0.286 | |
| β-blockers | 238 (19.4) | 226 (20.1) | 12 (11.7) | 0.037 | |
PCSK9 proprotein convertase subtilisin/kexin type 9, BMI body mass index, CAD coronary artery disease, FPG fasting plasma glucose, HbA1C hemoglobin A1C, ALT alanine aminotransferase, TC total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, NT-proBNP N-Terminal pro-brain natriuretic peptide, LVEF left ventricular ejection fraction, ACEI angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, p < 0.05 suggests significant difference